Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

Omega Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Opinion of Latham & Watkins LLP",
"Open Market Sale Agreement, between Omega Therapeutics, Inc. and Jefferies LLC",
"Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress"
07/13/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L..."
07/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/01/2023 8-K Quarterly results
02/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Opinion of Latham & Watkins LLP",
"Form of Securities Purchase Agreement"
11/08/2022 8-K Quarterly results
Docs: "Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights • First Patient Dosed in Phase 1/2 MYCHELANGELOTM I Trial of OTX-2002 • OTX-2002 Granted Orphan Drug Designation by U.S. FDA for the Treatment of Hepatocellular Carcinoma • OTX-2101 for MYC-Driven Non-Small Cell Lung Cancer Selected as Second Omega Epigenomic Controller™ Development Candidate • $148.3 Million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2022 CAMBRIDGE, Mass, November 8, 2022 -- Omega Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform, today ann..."
10/12/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
09/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/04/2022 8-K Quarterly results
Docs: "Omega Therapeutics, Inc. Condensed consolidated statements of operations and comprehensive loss Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Collaboration revenue from related party $ 476 $ — $ 743 $ — Operating expenses: Research and development 19,387 11,184 33,659 20,933 General and administrative 6,202 3,637 11,336 6,452 Related party expense, net 741 384 1,562 763 Total operating expenses 26,330 15,205 46,557 28,148 Loss from operations Other expense, net: Interest expense, net Change in fair value of warrant liability — — Other expense, net Total other expense, net Net loss $ $ $ $ Net loss per common stock attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average common stock used in net loss per share attributable to common..."
06/09/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2022 8-K Quarterly results
Docs: "Omega Therapeutics, Inc. Condensed consolidated statements of operations and comprehensive loss Three Months Ended March 31, 2022 2021 Collaboration revenue from related party $ 268 $ — Operating expenses: Research and development 14,191 9,748 General and administrative 5,406 2,745 Related party expense, net 630 449 Total operating expenses 20,227 12,942 Loss from operations Other expense, net: Interest expense, net Change in fair value of warrant liability — Other expense, net Total other expense, net Net loss $ $ Net loss per common stock attributable to common stockholders, basic and diluted $ $ Weighted-average common stock used in net loss per share attributable to common stockholders, basic and diluted 47,807,209 4,496,657 Comprehensive loss: Net loss $ $ Other comprehensive loss..."
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/10/2022 8-K Quarterly results
12/21/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Omega Therapeutics Reports Third Quarter 2021 Financial Results and Outlines Key Corporate Objectives  OTX-2002, the Company’s Lead Program Targeting c-MYC for the Treatment of Hepatocellular Carcinoma, is Currently Advancing Through IND-Enabling Studies; Good Progress Across Broad Pipeline  Established Strategic Collaboration with Stanford University School of Medicine for Potential Future Omega Epigenomic Controller™ Development Candidates to Further Diversify Pipeline  Strong Balance Sheet to Fund Pipeline of Omega Epigenomic Controllers with $234.3 Million in Cash and Cash Equivalents as of September 30, 2021 CAMBRIDGE, Mass, November 10, 2021 -- Omega Therapeutics, Inc. , a development-stage biotechnology company pioneering the first systematic approach to use ..."
11/08/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/10/2021 8-K Quarterly results
08/03/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy